Compare VLN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | PRQR |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | Israel | Netherlands |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 166.4M |
| IPO Year | N/A | 2014 |
| Metric | VLN | PRQR |
|---|---|---|
| Price | $1.35 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 606.5K | 296.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.37 | $11.37 |
| Revenue Next Year | $16.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $1.08 |
| 52 Week High | $3.34 | $3.10 |
| Indicator | VLN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 57.19 |
| Support Level | N/A | $1.65 |
| Resistance Level | $1.63 | $2.27 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 12.99 | 65.45 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.